Correlation Between Monopar Therapeutics and Plutonian Acquisition

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Plutonian Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Plutonian Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Monopar Therapeutics and Plutonian Acquisition Corp, you can compare the effects of market volatilities on Monopar Therapeutics and Plutonian Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Plutonian Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Plutonian Acquisition.

Diversification Opportunities for Monopar Therapeutics and Plutonian Acquisition

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Monopar and Plutonian is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Plutonian Acquisition Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Plutonian Acquisition and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Plutonian Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Plutonian Acquisition has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Plutonian Acquisition go up and down completely randomly.

Pair Corralation between Monopar Therapeutics and Plutonian Acquisition

If you would invest  2,385  in Monopar Therapeutics on October 29, 2024 and sell it today you would earn a total of  1,761  from holding Monopar Therapeutics or generate 73.84% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy5.56%
ValuesDaily Returns

Monopar Therapeutics  vs.  Plutonian Acquisition Corp

 Performance 
       Timeline  
Monopar Therapeutics 

Risk-Adjusted Performance

20 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Monopar Therapeutics are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Monopar Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.
Plutonian Acquisition 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Plutonian Acquisition Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Plutonian Acquisition is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Monopar Therapeutics and Plutonian Acquisition Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Monopar Therapeutics and Plutonian Acquisition

The main advantage of trading using opposite Monopar Therapeutics and Plutonian Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Plutonian Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Plutonian Acquisition will offset losses from the drop in Plutonian Acquisition's long position.
The idea behind Monopar Therapeutics and Plutonian Acquisition Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance